Is vemurafenib effective for hairy-cell leukemia?
['CONCLUSIONS: A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.', 'Our results strongly support and inform the clinical use of BRAF and MEK inhibitors in HCL.', 'The therapeutic approach of vemurafenib in treatment-refractory hairy cell leukemia is promising and offers an additional treatment option. ', 'Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib.', 'Recent identification of the recurrent V600E BRAF mutation in a majority of HCL patients has led some teams to evaluate the clinical potential of vemurafenib, a BRAF V600 specific inhibitor in a limited number of refractory HCL patients. Recently, we published the case of an HCL patient successfully treated with a low dose of vemurafenib.', 'We present here the successful retreatment of this patient with a second line of vemurafenib. Our data suggest for the first time that vemurafenib at the dose of 240 mg once a day could be sufficient to maintain a complete hematological remission after an initial induction treatment with low-dose vemurafenib (2 × 240 mg) daily without inducing major toxicity.', 'The discovery of the BRAF mutation has created a therapeutic target exploited by oral inhibitors like vemurafenib and dabrafenib.', '[Successful use of vemurafenib in a patient with resistant hairy cell leukemia].', 'The frequent persistence of phosphorylated ERK-positive leukemic cells in bone marrow at the end of treatment suggests bypass reactivation of MEK and ERK as a resistance mechanism.CONCLUSIONS: A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia. ', 'A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.', 'A short oral course of vemurafenib was highly effective in patients with relapsed or refractory hairy-cell leukemia.', 'The therapeutic approach of vemurafenib in treatment-refractory hairy cell leukemia is promising and offers an additional treatment option.']
['Yes, vemurafenib is highly effective in patients with relapsed or refractory hairy-cell leukemia.']
['yes']